Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Insulet $500 million stock offering
Davis Polk advised the underwriters in connection with the public offering of 2,369,668 shares of common stock of…
Cantel Medical $140 million convertible senior notes offering
Davis Polk the initial purchasers in connection with a Rule 144A offering by Cantel Medical Corp. of $140 million…
Alector $150 million at-the-market offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Alector, Inc. of…
AtriCure $201.2 million follow-on offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a SEC…
DexCom $1.05 billion convertible notes offering
Davis Polk advised the representatives of several initial purchasers in connection with a Rule 144A offering by DexCom,…
Affimed $50 million at-the-market offering program
Davis Polk advised the sales agent in connection with the establishment of an SEC-registered at-the-market offering…
Zoetis $1.25 billion senior notes offering
Davis Polk advised the joint book-running managers, in connection with an SEC-registered offering by Zoetis Inc. of $750…
Ayala Pharmaceuticals $55 million IPO
Davis Polk advised the underwriters in connection with the $55 million initial public offering of 3,666,667 shares of…
Anthem $2.5 billion senior notes offering
Davis Polk advised the representatives of the several underwriters on an SEC-registered offering by Anthem, Inc. of $2.5…
Eli Lilly $1 billion notes offering
Davis Polk advised the joint book-running managers in connection with a registered offering by Eli Lilly and Company of $1.0…